Open AccessEfficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial
Author(s) -
Messerli Franz H.,
Bakris George L.,
Ferrera R. David,
Houston Mark C.,
Petrella Robert J.,
Flack John M.,
Sun William,
Lee EunMee,
Neutel Joel M.
Publication year - 2006
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2006.05636.x
Subject(s) - atorvastatin , amlodipine , medicine , dyslipidemia , placebo , blood pressure , lisinopril , pharmacology , adverse effect , randomized controlled trial , angiotensin converting enzyme , disease , alternative medicine , pathology
The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia. Phase one was an 8‐week, double‐blind, double‐dummy, placebo‐controlled period whereby patients received amlodipine 5 mg, atorvastatin 10 mg, amlodipine 5 mg and atorvastatin 10 mg, or placebo. Thereafter, all patients received single‐blind amlodipine 5 mg and atorvastatin 10 mg for 8‐weeks, followed by 12 weeks of open‐label treatment where doses could be titrated to improve low‐density lipoprotein cholesterol and blood pressure control. A total of 847 patients entered the double‐blind phase. At Week 8, 45% of the patients receiving amlodipine 5 mg and atorvastatin 10 mg reached both their blood pressure and low‐density lipoprotein cholesterol goals, compared with 8.3% with amlodipine (p<0.001), 28.6% with atorvastatin (p<0.001), and 3.5% with placebo. At 28 weeks, 67.1% of patients coadministered amlodipine and atorvastatin (mean doses, 7.6 mg and 28.4 mg, respectively) achieved both targets. Framingham estimated 10‐year risk of coronary heart disease declined from baseline levels of 15.1% to 6.9% at Week 28. Following coadministered treatment, the adverse events reported were similar to either agent alone. Concomitant administration of amlodipine and atorvastatin is an effective and well tolerated treatment for coexisting hypertension and dyslipidemia.